Mixture Of Interferon Alpha 2B With Other Modified Sequences Thereof
Summary
PharmaEssentia Corporation filed patent application US20260109749A1 covering a modified interferon alpha 2B composition and associated manufacturing method involving deamidated amino acids. The application, listing six named inventors including Ko-Chung Lin and Ming-Pin Hsu, was published on April 23, 2026 with a filing date of October 17, 2025. The application is assigned number 19361468 and falls under CPC classifications C07K 14/56, C12P 21/02, and A61K 38/00.
“A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with deamidated amino acids is disclosed herein.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
PharmaEssentia Corporation filed USPTO patent application US20260109749A1 for a modified interferon alpha 2B composition and manufacturing method incorporating deamidated amino acids. The application names six inventors and has been assigned CPC classifications relevant to proteins and pharmaceutical compositions.
This is a patent application publication, not a granted patent. It does not confer any exclusive rights or create compliance obligations for other parties. Interested parties wishing to manufacture similar compositions should monitor the application status and conduct freedom-to-operate analysis upon any future grant.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Mixture Of Interferon Alpha 2B With Other Modified Sequences Thereof
Application US20260109749A1 Kind: A1 Apr 23, 2026
Assignee
PharmaEssentia Corporation
Inventors
Ko-Chung Lin, Ming-Pin Hsu, Yu-Kuei Tsai, Yi-Te Yo, Jiing-Guang Chuang, Shin-Jye Lee
Abstract
A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with deamidated amino acids is disclosed herein.
CPC Classifications
C07K 14/56 C12P 21/02 A61K 38/00
Filing Date
2025-10-17
Application No.
19361468
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.